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Blood transfusions are routinely done in every medical regimen and a worldwide
established collection, processing/storage centers provide their services for the same.
There have been extreme global demands for both raising the current collections
and supply of safe/adequate blood due to increasingly demanding population. With,
various risks remain associated with the donor derived blood, and a number of post
collection blood screening and processing methods put extreme constraints on supply
system especially in the underdeveloped countries. A logistic approach to manufacture
erythrocytes ex-vivo by using modern tissue culture techniques have surfaced in the
past few years. There are several reports showing the possibilities of RBCs (and
even platelets/neutrophils) expansion under tightly regulated conditions. In fact, ex vivo
synthesis of the few units of clinical grade RBCs from a single dose of starting material
such as umbilical cord blood (CB) has been well established. Similarly, many different
sources are also being explored for the same purpose, such as embryonic stem cells,
induced pluripotent stem cells. However, the major concerns remain elusive before the
manufacture and clinical use of different blood components may be used to successfully
replace the present system of donor derived blood transfusion. The most important factor
shall include the large scale of RBCs production from each donated unit within a limited
time period and cost of their production, both of these issues need to be handled carefully
since many of the recipients among developing countries are unable to pay even for the
freely available donor derived blood. Anyways, keeping these issues in mind, present
article shall be focused on the possibilities of blood production and their use in the near
future.
Keywords: RBCs, ex-vivo erythrocytes, manufacturing blood, hematopoietic stem cells, induced pluripotent stem
cells
INTRODUCTION
Initially, started by Harvey’s studies of blood circulation system,
blood transfusion began in the 17th century with animal blood
transfusion experiments. The first fully documented report on
blood transfusion in humans was from Dr. Jean-Baptiste Denys,
who in 1665 successfully transfused blood from a sheep in a 15
years old boy. Though, he could not succeed in later transfusions
as recipients died after transfusions were made. In similar studies,
Dr. Richard Lower demonstrated the effects of changes in blood
volume in circulatory function and developed methods for cross-
circulatory study of animals. The first successful human blood
transfusion was reported by Dr. James Blundel (1818) between a
married couple for a postpartum hemorrhage. However, in 1901,
the breakthrough was achieved in human transfusion with the
discovery of blood group antigen by Austrian researcher Karl
Landsteiner, who discovered that red blood cells got clumped
when incompatible blood types were mixed and immunological
reaction occurred if the recipient of a blood transfusion had anti-
bodies against the donor blood cells. This “Nobel Prize” (1930)
winning discovery made it possible to determine blood type and
paved the way for safe blood transfusions. Since then many other
blood groups have been discovered. Following to these discover-
ies a number of blood banks were established during 1940–1950s
and it is an inevitable part of all the modern clinical modalities
(Alter and Klein, 2008).
The global blood collection was reported to be about
103 million units (www.who.int/worldblooddonorday/en/)
(Department of Health and Human Services, 2010, 2013;
World Health Organization, 2011). The quality and quantity
of donor derived blood collection remain unevenly scattered
in economically developed and developing countries. Almost
50% of these blood collections is made in developed countries,
which accommodate only a mere 15% fraction of the world’s
population. Presently, the blood collection seems to be sufficient
in economically developed countries. It is supported by reports
showing 30,000 annual blood donations on an average per
blood center through ∼8000 blood centers scattered in 159
high-income countries (Department of Health and Human
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Services, 2010, 2013). For example, in U.S. the total no. of blood
unit collected were 5% more than the actual transfusion made
during year 2011 (Department of Health and Human Services,
2013). On the contrary, this number of collections/per center is
very less (3700) in developing countries. As per WHO report 82
low income and middle income countries have only 10 donations
per 1000 people in the population that would remain highly
insufficient to supply a comparable large population residing
in these countries (World Health Organization, 2011). Further,
the screening facilities are very much inefficient in most of the
developing countries. As per WHO record, 39 countries are not
able to screen all blood donations for one or more of the follow-
ing transfusion-transmissible infections (TTIs): HIV, hepatitis
B, hepatitis C, and syphilis (Department of Health and Human
Services, 2013). Again, there are only 106 countries which have
national guidelines on the appropriate clinical use of blood. It
would be worth noticing that only 13% of low-income countries
have a national haemovigilance system to monitor and improve
the safety of the transfusion process. Moreover, the blood supply
may look sufficient for the time being in developed countries, it
likely becomes inefficient to keep supporting a rapidly growing
proportion of elderly population (>60 years age) and burgeoning
demand for blood transfusions for surgical treatments by the
year of 2050 (U.S. Census Bureau, 2004; Ali et al., 2010).
One of the major challenges in clinical settings is to find blood
group compatibility for more than 30 blood group system (308
recognized antigens) including ABO&Rh antigens (Daniels et al.,
2009).
There are a number of situations such as rare phenotypes,
hemoglobinopathies, polytransfusion patients and polyimmu-
nization that may result in significant complications (World
Health Organization, 2011) adding more complexity to the sup-
ply constraints. Recent technologies such as antigen masking and
enzymatic cleavage to generate universal donor blood groups (O
and RhD antigens) have been proposed. But thesemethods are yet
to be developed (Bagnis et al., 2011). While keeping these issues
in mind, it is worth noticing that the donated blood is tested for
various kinds of infections before any transfusion could be made
[e.g., HIV-1, HIV-2, HTLV-1, HTLV-2, Hepatitis B, Hepatitis C,
Syphilis (T pallidum), Chagas disease (T cruzi), and West Nile
Virus, Cytomegalovirus (CMV)], and a number of precaution-
ary measures are followed during transfusion procedures. Even
then blood transfusions are often associated with several compli-
cations (Alter and Klein, 2008;WorldHealth Organization, 2011).
These complications not only compromise the quality of treat-
ment, but may add to the overall cost of the regime also which
remain associated with it in any clinical setting (Department of
Health and Human Services, 2010). This is true even in the devel-
oped countries where 0.24 % transfusion has been reported to
be associated with adverse reactions (Department of Health and
Human Services, 2013). For example, adverse events from trans-
fusions in the US only may account for approximately $17 Billion
every year. These complications depend upon the patient status
or specific transfusion quantity involved. These situations have
evoked researchers to develop alternate methods to get blood
from various non-donor derived sources. In the search of blood
alternates researchers have developed various artificial molecules
mimicking functionalities of blood RBCs. The majority of these
molecules is either hemoglobin based oxygen carriers or perfluo-
rocarbon solutions. Hemoglobin based carriers are reported to be
inefficient as compared to the oxygen carrying capacity of native
RBCs. Whereas, perflorocarbons could not become popular due
to their limited functional applications (Winslow, 2006; Henkel-
Honke and Oleck, 2007; Natanson et al., 2008; Silverman and
Weiskopf, 2009; Castro and Briceno, 2010).
Ex vivo expansion of erythrocytes or manufacturing blood
from stem cell is the most attracting approach among the global
research community for the last few years. The basis for the prin-
ciple that ex vivo cultivated RBCs (or other blood cells) may
be of clinical use was provided by Nakamura and his colleagues
who have demonstrated that RBCs derived from the immobilized
ESCs cell line can protect mice from lethal anemia (Hiroyama
et al., 2008). Recently, the proof-of-concept was described by
first in-human blood transfusion using ex-vivo generated RBCs
(Giarratana et al., 2011). In a major landmark study, Giarratana
et al. shown the survival capacity of ex vivo cultivated RBCs in
humans. As described by them, the CD34+ cells obtained from
volunteer donors as an aphaeresis product were cultured in a
serum free media (with the addition of Stem cell factor (SCF),
Interleukin-3 (IL-3), and Erythropoietin (EPO) resulting into
2ml of blood RBCs equivalent (1010 cells) under GMP condi-
tions. The ex vivo expanded RBCs were labeled with 51Cs to trace
their fate in patients as approved by FDA U.S. (Giarratana et al.,
2011) and demonstrated to be comparable with any native RBCs
transfusion. These findings established the proof-of-concept for
clinical utilization of ex vivo generated RBCs globally. As dis-
cussed in the next section, a number of methods have been
demonstrated so far (Figure 2), which ensure the feasibilities
of ex vivo RBCs expansion from various source materials (e.g.,
CD34+ HSCs, Embryonic stem cells, and IPSCs) (Figure 3).
There are various factors which essentially regulate the yield and
the level of RBCs maturation through these protocols. Reports
are there, showing numerical expansion of erythrocyte precursors
up to ∼0.5 transfusion unit/donation from UCB CD34+ cells,
and approximately 2 million fold expansions of enucleated ery-
throcytes functionally comparable to native RBCs through slight
modification of culturing techniques (Neildez-Nguyen et al.,
2002). Further, large scale production (up to 10 transfusion unit)
from two units of UCB have been demonstrated by technically
complex protocols (described in later sections) which presently
may appear ill suited from the commercial scale production point
of view but strengthen the concept that with the advancement of
techniques sufficient transfusable units may be produced (Fujimi
et al., 2008). Besides that, RBCs precursors, cellular intermedi-
ates/nucleated erythroid precursors are generated through these
protocols, which may also be of use if transfused. It is expected
that these cells are likely to become functionally matured in vivo
while interacting with internal factors governing their matura-
tion. The same has been reported both in human and animal
models (Ende and Ende, 1972; Neildez-Nguyen et al., 2002).
Conceptually, the maturing cells along with functionally matured
cells may aid to maintain the cellular content at the time of trans-
fusion. These maturing cells may proliferate and each cell may
give rise to 4–64 cells before they get enucleated and functionally
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matured in vivo. This hypothesis is supported by the data avail-
able from clinical observations in developing countries where
40–80ml of compatible CB blood (containing 4–7 ×1010 RBCs
and 2–8 ×109 erythroblast cells) is occasionally used for trans-
fusion in emergent conditions (Ende and Ende, 1972). Together,
these reports strengthen the concept that ex vivo RBCs expansion
likely support the different clinical short-comes to exist due to
limited supply and various rare blood based disorder.
However, a number of factors such as technological barri-
ers associated with large scale production and per unit pro-
duction cost remain to be considered in order to support a
large population. The present scale of RBCs production would
require to be enhanced several times in a more cost-effective
and timely manner. Commercial production of blood may lack
essential background financial support in developing countries
which are suffering from even more sensitive issues. Moreover,
in the absence of more realistic, achievable goals it may become
hard even in the capitalistic developed countries. Present arti-
cle focuses on various issues related to current methods and
their feasibilities to realize limited “blood pharming” in near
future.
ERYTHROPOIESIS IN VIVO
Hematopoiesis, a dynamic process, is regulated both temporally
and spatially. It may be classified as “primitive hematopoiesis” in
featus where specified cells termed as “blood islands” are gener-
ated by yolk sac (YS). In YS, nucleated RBCs exclusively expresses
embryonic Hbs (Gower-1, Gower-2, and Hb Portland) are gener-
ated for a small period of time. Following to that, a second wave of
hematopoiesis or “definitive hematopoiesis” produce hematopoi-
etic stem cells, which have the potential of transfusion and
includes enucleated RBCs along with various other hematopoietic
cells. This event takes place largely in the fetal liver and up to a lit-
tle extent in YS. In later stages of featus development Definitive
hematopoiesis occurs in bone marrow (BM) and that serves as
the only site of hematopoiesis in adults through their life. The
hematopoietic cells from fetal and adult definitive hematopoietic
stages may be differentiated on the basis of their HB contents. In
the fetus hematopoiesis α and γ globins, (the components of fetal
Hb) (Hb F), are expressed, and in the later β globins (the com-
ponents of adult-type) (HbA), are expressed (Palis, 2008; Baron
et al., 2012).
Erythropoiesis or generation of RBCs includes hematopoietic
progenitor cells, which are first differentiated into committed ery-
throid progenitors and thereafter proliferate/converted to func-
tional red blood cells in a highly regulated hierarchalmanner. This
dynamic process is tightly regulated through a number of growth
factors which ensure the maintenance of regular homeostasis of
the RBCs mass.
The entire process of erythropoiesis may be defined to
occur in three stages: (1) Erythropoietic commitment of HSCs:
this includes development of erythroid committed blast cells
from multipotent hematopoietic progenitors; (2) Division and
differentiation of these morphologically identifiable erythroid
progenitor cells; and (3) Terminal differentiation including cel-
lular morphological changes such as enucleation, to produce
reticulocytes and ultimately maturation: of RBCs (Figure 1).
The Hematopoietic stem cells are generated in YS and may
be differentiated into a common myeloid progenitor that, in
turn, gives rise to bipotent progenitors restricted to either the
granulocyte/macrophage or the erythroid/megakaryocytic path-
ways (Suda et al., 1983; Debili et al., 1996; McLeod et al., 1996;
Akashi et al., 2000). A comparable stage of development defined
in vitro using cytokine containing semisolid medium (Figure 1)
is the colony-forming unit granulocyte, erythroid, macrophage,
megakaryocytic (CFU-GEMM) precursor that gives rise to bipo-
tent progenitors restricted to either granulocyte/macrophage or
erythroid/megakaryocytic pathways (Suda et al., 1983; Debili
et al., 1996;McLeod et al., 1996). Those progenitors which express
erythropoietin receptor (EPOR) remain responsive to erythropoi-
etin (EPO) and are committed to the erythroid/megakaryocytic
pathway.
On the other hand, EPOR deficient progenitor cells are com-
mitted to themyeloid pathway. The burst-forming unit–erythroid
(BFU–E), which gives rise to colony-forming unit–erythroid
(CFU–E) is termed as the most immature erythroid-restricted
progenitor. Among them, early BFU–E (blast-like cells) are highly
proliferative, and give rise to clustered burst colonies of up to
20,000 cells in semisolid culture assays.
However, BFU–E bear comparatively small number of EPOR
but later progenies (daughter cells) derived from them acquire
a high expression level of EPOR and become EPO responsive,
transferrin receptor positive, and begin to express hemoglobin
(Heath et al., 1976; Lichtman et al., 2007). Later on, CFU–
E are derived from these cells, which are highly responsive
to EPO, but generate smaller colonies, and express many of
the gene products required for definitive erythroid develop-
ment (Figure 1). There are reports describing a cell division
stimulating anti-apoptotic role of EPO in late-stage erythroid
cells derived from CFU–E. At this stage of development cells
may start the synthesis of hemoglobin and acquire cytoskeletal
proteins in tissue culture systems. Moreover, cellular adhesion
molecules are expressed in these cells that help define them as
nucleated erythroblasts. Thereafter morphologically identifiable
nucleated erythroid precursor become visible, which progress
from the pro-erythroblast to basophilic, polychromatophilic, and
orthochromatic cell forms leading to the reticulocyte (Figure 1)
(Stephenson et al., 1971; Lichtman et al., 2007; Jing et al.,
2013).
Erythroid differentiation encompasses four distinct major cel-
lular processes such as, (1) the accumulation of hemoglobin that
participates in driving the basophilic to acidophilic cytoplasmic
changes seen during maturation, (2) limited erythroblast expan-
sion, (3) a continued decrease in cell size, (4) and nuclear conden-
sation leading to their final enucleation. These highly regulated
developmental changes take place in the microenvironment of
BM niche where “erythroblast islands” are closely associated with
macrophages that serve as stromal or nurse cells (Bessis et al.,
1978; Manwani and Bieker, 2008; Rhodes et al., 2008). These
erythroid development stages end up with the exit of reticulo-
cytes from the marrow, which now enter the circulation and get
matured into erythrocytes. The characteristic features of this stage
include disassembly of ribosomes, Golgi bodies, and other cel-
lular machinery, removal of organelles, enucleation, changes in
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FIGURE 1 | Hierarchy of erythropoietic development in vertebrates. In
adult Bone Marrow, committed progenitors arising from hematopoietic
stem cells give rise to erythroblasts, and as the progeny of a stem cell
progress through development, there is a loss of their multipotency
while increasing lineage restriction. The various cellular stages in
erythrocyte development are identified by their ability to form colonies in
semisolid medium supplemented with specific cytokines and by cell
surface markers.
the cytoskeleton leading to the classic biconcave discoid shape,
and then release into the circulation (Department of Health and
Human Services, 2013). Terminal maturation takes place in the
erythroblast islands, which involves participation macrophages
of with maturing erythrocytes (Bessis et al., 1978; Manwani and
Bieker, 2008; Rhodes et al., 2008).
The mature erythrocyte have a life span of 120 days in
blood circulation, and afterwards “senescence” occurs reflected
through changes in surface antigen expression or physical char-
acteristics of the cell triggering their removal from the blood
by macrophages/reticuloendothelial system (Gifford et al., 2006).
Thus, hematopoiesis is regulated through changes in body com-
partments during mammalian development, from embryo to
adult, and depending on the age of development, special-
ized microenvirnmental niches precisely regulate hematopoietic
development (Migliaccio et al., 1986; Palis and Yoder, 2001; Baron
and Fraser, 2005; Mikkola et al., 2005; McGrath and Palis, 2008).
EX VIVO ERYTHROPOIESIS: AN OVERVIEW
There has been considerable progress in the field of developing
biological control over the expansion of erythrocytes to generate
terminally differentiated, fully functional RBCs (Migliaccio et al.,
2012). The in vivo hematopoietic development process have been
studied (Figure 1) and an in depth knowledge of the generation
of erythroblast regulated through various growth factors have
paved the way to mimic the process in vitro (Lodish et al., 2010).
Altogether, these reports demonstrated the enormous potential
inherited by three major cell types including (i) CD34+ HSPCs,
(II) Embryonic stem cells/induced pluripotent stem cells, and
(III) immortalized erythroid precursors which can be differen-
tiated into erythroid lineages by using almost similar/overlapping
protocols (Figure 2) (Table 1). Regardless of their types, stem cells
are promoted to become erythroid progenitor in three basic steps
viz. commitment, expansion, and maturation. There are a num-
ber of reports showing use of various cytokines/growth factors
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FIGURE 2 | The various methods/protocols described so far for the
ex vivo RBCs expansion. As discussed in the main text, manufacturing
blood may involve various step which are to be categorized in three main
phases as depicted in the figure. In phase 1: initial source material is to be
collected from a variety of source material(s) on the basis of their availability,
suitability, and expansion potential and grown in medium generally
supplemented with growth factors to enhance HSCs proliferation:
subsequently these cells are cultured in the presence of Erythropoietin to
induce their differentiation and maintenance into erythropoietic progenitor
stage. Finally, in Phase 3 cultures these Erythropoietic progenitors may be co
cultured with murine/human stromal cell line support to induce their
maturation and enucleation resulting into mature RBCs. These RBCs are
evaluated for their biochemical properties and various antigenic profiles to
ensure their nativeness.
(SCF and EPO are most common) to generate variable yields of
immature progenitors or mature RBCs with or without using ani-
mal/human derived feeder coculture system (Figure 2). Recently,
a new concept of transdifferentiation (directly differentiating
human fibroblast cells into erythroblasts) has been shown to
bypass the HSPC state (Figure 3) (Szabo et al., 2010). Although
promising, but the technique remains to be evaluated for their
potential to generate large scale RBCs. Most of these protocols
suffer from similar problems such as degree of enucleation or ery-
throcyte formation, predominate form of Hb expressed by them,
use of animal derived products such as serum and feeder cell
coculture, and clinical transfusion related problems such as blood
typematching and unavailability of sufficient number of RBCs for
transfusion. All these issues can be summarized in the following
sections.
CD34+ HEMATOPOIETIC CELLS FROM VARIOUS SOURCES AND THEIR
USE FOR EX VIVO RBCs CULTURE
CD34+ cells from peripheral blood (PB), cord blood (CB), and
BM have been in use for clinical transplantations for more than
two decades (Carmelo et al., 1995). Initialed by Fibach et al.
the methods to generate RBCs from CD34+ HSPCs have been
existing for a long time (Fibach et al., 1989, 1991; Wada et al.,
1990). Douay et al. were quick to demonstrate functional char-
acteristics of the erythrocytes generated by CB derived CD34+
HSPCs (Douay, 2001; Neildez-Nguyen et al., 2002). Their studies
confirmed a higher erythrocyte generating potential in compar-
ison to myeloid precursors with low (4%) enucleation efficiency
(Neildez-Nguyen et al., 2002). Giarratana et al. further modified
the protocol and demonstrated 90% enucleation efficiency in a
similar 3 step method for adult blood/BM derived CD34+ cells
(Giarratana et al., 2005) by co-culturing them with murine stro-
mal cell line (MS5) or Humanmesenchymal stem cells (HuMSC).
The procedure resulted in, 20,000 fold, 30000 fold and 2 × 105
fold increment in the erythrocytic cell generation when BM,
GM-CSF mobilized PB, and CB derived CD34+ cells were used
respectively (Douay and Andreu, 2007; Douay and Giarratana,
2009; Douay et al., 2009). This group further reported 5–10 units
of blood cells on prolonged culture with feeder cell coculture
system (Douay and Andreu, 2007; Douay and Giarratana, 2009;
Douay et al., 2009). The cells were reported to have native RBCs
like functional characteristics as described by normal glucose-
6-phosphate dehydrogenase (G6PD) and Pyruvate Kinase (PK)
enzyme levels, membrane deformability and oxygen dissociation
characteristics. This was also evident by their similar survival
rate in non-obese diabetic/severe combined immunodeficient
(NOD/SCID) mice following to intraperitoneal infusion of car-
boxyfluorescein diacetate succinidyl acetate (CFSE) labeled cells.
These methods suffer from two major drawbacks such as (i)
use of animal serum and co-culture system and (ii) low yield of
functionally matured RBCs per unit of blood cells, which tempted
researchers to identify more defined cocktail of growth factors to
achieve a better control over erythrocytes proliferation and dif-
ferentiation. Malik et al. demonstrated generation of ∼10–40%
enucleated erythrocytes by enriched CD34+ cells from CB, PB,
and BM (Malik et al., 1998) in a serum free liquid culture system
(with Flt-3, GM-CSF, EPO). This report indicated the possibilities
of generating erythrocytic progenitors in the absence of animal
derived serum that is strongly recommended by most clinicians.
Following to these reports 105 − 1.5 × 108 folds erythroid cell
expansion have been reported in similar serum free environment.
(Panzenböck et al., 1998; Freyssinier et al., 1999).
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FIGURE 3 | An overview of the various approaches used for ex vivo
Erythropoiesis. The different approaches are in use for develoing large
amount of transfusable clinical grade RBCs include CD34+ HSPCs (from CB,
PB, BM), ESCs/IPSCs derived erythroid progenitors, and highly expanding
erythroid progenitors due to stress erythropoiesis. All these approaches has
been discussed in detail in text.
Fujimi et al. demonstrated massive production of terminally
matured erythrocytes from CD34+ CB cells in the serum free
environment while avoiding xenogenic feeder by using hTERT
transduced human stromal cell line (Fujimi et al., 2008). These
methods could result in massive growth of 6 × 1012 RBCs from
one unit of CB and also the highest RBC number per starting
cell (3.52 × 106) in any static culture. However, use of the AB
blood group, serum to derive macrophages in a 14 days cul-
ture and an additional step of magnetic separation leaves this
method ill-suited for the scaling up purposes. Beak et al. showed
up to 64% enucleation efficiency by using CB or BM derived
mesenchymal stem cells as feeder layer which would require an
additional MSCs donor for the feeder cells and thus may not
be suitable for large scale production procedures (Baek et al.,
2008). Xi et al. has demonstrated an in vitromodel of human ery-
thropoiesis to study the erythroid differentiation in normal and
pathological conditions (Xi et al., 2013). CD34+ cells were shown
to undergo up to 35 doublings in a prolonged 50 days culture in
serum free media supplemented with EPO, synthetic glucocorti-
coid Dex, IGF-1, SCF, and iron saturated human transferrin. In
a subsequent step, matured RBCs could be generated by cocul-
turing erythroid progenitors with human fetal liver stromal cells.
The procedure resulted in 109 fold expansion of erythrocytes (Xi
et al., 2013).
Recent findings have indicated a significant erythropoietic
potential in the CD34neg cell fraction which should also be
exploited to enhance the production (Leberbauer et al., 2005;
Van den Akker et al., 2010; Tirelli et al., 2011a). Leberbauer
et al. described a culture method which exploited the signal
transduction cascades of stress erythropoiesis, achieving a 109-
fold expansion of erythroblasts of CB cells without prior CD34+
isolation (Leberbauer et al., 2005). Akker et al. describe a cul-
ture method modified from Leberbauer et al, and obtained a
homogenous population of erythroblasts from peripheral blood
mononuclear cells (PBMC) without prior purification of CD34+
cells. This pure population of immature erythroblasts can be
expanded to obtain 4 × 108 erythroblasts from 1 × 108 PBMC
after 13–14 days in culture. Upon synchronizing differentia-
tion, high levels of enucleation (80–90%) and low levels of cell
death (<10%) are achieved. These studies indicated CD34Neg
cells as most significant early erythroid progenitor popula-
tion (Van den Akker et al., 2010). Tirelli et al. also demon-
strated significant enhancement (log scale) in the erythroid cell
generation by using total MNC in Human Erythroid Massive
Culture (HEMA) (Tirelli et al., 2011a). The careful pheno-
types examination showed a significantly more erythropoietic
potential of CD34neg population as compared to CD34+ cells
(Tirelli et al., 2011a).
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One of the major criteria for calculating efficiency of various
ex vivo expansion protocols remains to describe the degree of
enucleation of these maturing erythrocytic cells. The interactions
with macrophages/stromal cells play a crucial role in develop-
ing high degree of enucleated erythrocytes as described through
various researchers (Kawano et al., 2003). However, most of the
stromal cells support used by various researchers are of animal
origin and may conflict with the interests of the few clinicians
to describe these cells as clinical grade blood products. These
issues raised the interest of the research community to define
methods without a need for animal based products. Miharada
et al. who showed generation of 4.5 × 1012 erythroid cells from
5 × 106 CD34+ cells in the absence of any feeder cell layer or
macrophage cells by using VEGF-1, TGF-1 and a glucocorticoid
antagonist Mifepriostone to avoid dependence of these meth-
ods on feeder cells (Miharada et al., 2006). Maggakis-Kelemen
et al. also reported similar results to improve the yield by using
DMSO, Ferrous Citrate and Transferrin in the culture medium
(Maggakis-Kelemen et al., 2003). Though these factors signifi-
cantly increased the yield, but precursor cells shown higher degree
of deformability and reticulocytes/erythrocytes were demon-
strated to have reduced shear modulus. Beak et al. demonstrated
the use of a polymer Poloxamer 188 to yield >95% enucleated
RBCs in similar protocols without using any feeder cell support
(Baek et al., 2009). Poloxamer 188 enhances the production by
protecting cellular lysis during nucleation due to hydrodynamic
stress. It provides support to the membranes and protects frag-
ile cells from lysis at the time of enucleation. Thus, it seems that
a large number of terminally matured clinical grade RBCs may
be obtained regularly with the advent of similar protocol, while
introducing newer alternatives at different levels of their expan-
sion. Earlier, similar results were reported by Timmins et al. who
demonstrated feeder free culture system by using a bioreactor and
resulted in a massive 500 units (108 fold) per UCB donations
(Timmins et al., 2011).
While considering these findings, it seems that both CB and
PB derived CD34+ cells possess enormous expansion potential
with some marginal differences such as the predominant form
of Hb expressed and % yield of enucleated RBCs. For exam-
ple, RBCs from CB derived cells are predominantly rich in fetal
Hb (Neildez-Nguyen et al., 2002; Giarratana et al., 2005, 2011),
whereas, RBCs from PB derived cells majorly express adult Hb
(Giarratana et al., 2005, 2011). Apart from that, there have been a
significant difference in the expansion potential of CB/PB derived
HSPCs. With the current technologies available for their expan-
sion PB derived cells have shown comparatively low (120,000
fold) yields (Giarratana et al., 2005). In contrast, CB derived cells
are reported to expand up to 2 million folds. Even more, a single
unit of CB derived cells can result into 500 units of transfusable
RBCs (Timmins et al., 2011). However, the later method has not
been applied for the PB derived cells so far. Thus, it seems that CB
shall provide a better option for initial source to be selected under
present circumstances, and, if presence of fetal Hb is acceptable
(Conley et al., 1963; Weatherall and Clegg, 1975; Thomson et al.,
1998; Foeken et al., 2010), it shall remain the most attractive alter-
nate for RBCs expansion protocols. The infrastructure for CB
collection is well developed. According to a report in 2010, about
4,50,000 CB units were collected through 131 CB Banks world-
wide (Foeken et al., 2010). There is enough information available
through these blood bank registries regarding the blood types and
combinations of the antigen present on these blood groups for
each CB donation. Though, the exact percentage for each rare
blood type may not be available and even if the specialized donor
could be found for each rare antigen combination, it may be dif-
ficult to fulfill a regular demand of transfusion in every 3–4 weeks
due to the limited life span of these cells. However, even then a
large fraction of the population may be benefitted from the exist-
ing technologies without any risk for rare antigen combinations.
EMBRYONIC STEM CELLS AND INDUCED PLURIPOTENT STEM CELLS
Embryonic stem cells (Thomson et al., 1998) and induced
pluripotent stem cells (Takahashi and Yamanaka, 2006; Takahashi
et al., 2007) are defined as immortal cells with the self-renewing
capacity and if the requisite growth environment is made avail-
able have potential to differentiate into all kinds of cells of the
organism. Embryonic stem cells were first isolated from 3–4 days
old Blastocysts (Takahashi et al., 2007), and subsequent stud-
ies by various research groups described their capabilities to
be maintained indefinitely in cultures due to high telomerase
activities. Takahashi and Yamanaka’s group firstly demonstrated
iPSCs or ESC-like cells that may be generated by reprogram-
ming somatic cells. They showed the transformation of murine
fibroblast cells in to ESC by transfection of transcription fac-
tors such as POUSF-1, KLF-4, SOX-2,and Myc (Takahashi and
Yamanaka, 2006; Takahashi et al., 2007). These cells were further
demonstrated to form teratoma on infusion in NOD-SCID mice
and differentiation into cells from all the three germ cell lines
respectively (Okita et al., 2007; Wernig et al., 2007). Generation
of Human IPSCs (hips) was also defined by transformation of
human neonatal or adult fibroblast by the same set of genes
(Takahashi et al., 2007). Yu et al. also generated of hIPSCs from
fibroblast cell by using lentivirus mediated transfection of Nanog
and LIN28 to reduce the undesired effects of c-Myc (Yu et al.,
2007). Subsequently, other methods of generating IPSCs have
been reported such as ectopic expression of the same set of
transcription factors (Stadtfeld et al., 2008) and use of excis-
able transposons (Lacoste et al., 2009). Alternatively, these factors
could also be provided from outside attached to a cell penetrating
peptide sequence (Zhou et al., 2009). Together these cells provide
an alternate to generate HSPC. The mononuclear cells (CB/PB)
may be reprogrammed in IPSCs and in subsequent procedure
human IPSCs could be differentiated into CD34+CD45+ HSPC
by using similar protocols used for ESCs (Ng et al., 2005; Choi
et al., 2009).
There are a number of groups who have demonstrated
hematopoietic differentiation of hESCs/IPSCs (Lu et al., 2008;
Chang et al., 2011; Kobari et al., 2012) (Table 1). These methods
can largely be grouped into two categories of (1) Embryoid body
formation through suspension culture of hESCs without feeder
cells, and (2) co culture of hESCs with murine stromal cell lines
such as S17 or OP9 (Chadwick et al., 2003; Vodyanik et al., 2005,
2006; Chang et al., 2006). In the first approach, cells grow in sus-
pension culture resulting in 3-dimensional structured aggregates
of differentiating cells called Erythroid Bodies (EBs) (Vodyanik
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et al., 2005). Chang et al. described a method of generating
erythroid cells from embryoid bodies (Vodyanik et al., 2006).
Nakamura’s group described a method for the generation of enu-
cleated erythrocytes from mouse ESCs (Hiroyama et al., 2008)
which was followed by several researchers who demonstrated
procedures for the generation of enucleated erythrocytes by using
human ESCs (Lu et al., 2008; Qiu et al., 2008; Lapillonne et al.,
2010; Dias et al., 2011)
During last 10–11 years significant development has occurred
in the procedure to develop hESCs/iPSCs and high yields of
approximately up to 1011–1012 erythrocytic cells have been
achieved from a single plate of hESCs (Lu et al., 2008). While
comparing these reports, most procedures have indicated an
important role of erythropoietin (along with other growth fac-
tors BMP-4, VEGF, bFGF etc.) and coculturing themwith a feeder
cell to derive sufficient yield of enucleated RBCs (Kaufman et al.,
2001; Keller, 2005; Ng et al., 2005; Ledran et al., 2008; Zambidis
et al., 2008). His can be a Co cultured with a number of feeder
cells available, including mesenchymal cell Murine stromal cell
line S17, OP9 (Vodyanik et al., 2005, 2006). YS endothelial cell
lines (Kaufman et al., 2001), cell lines derived from murine AGM
stroma, liver or other developmental niche (Ledran et al., 2008)
(Murine AGM derived AM20-1B4 cells) are described as best
supporting cells providing higher yields.
In order to achieve animal cell free clinical grade blood prod-
ucts efforts have been made by various researchers. It has been
described that the use of feeder cell layer derived from human tis-
sue itself e.g., human foreskin derived fibroblast cells support to
generate similar results (Amit et al., 2003; Hovatta et al., 2003;
Koivisto et al., 2004). Genbacey and his colleagues, has reported
expansion of hESCs in serum free conditions by growing them on
cells derived from human early gestation placental fibroblast cells
or human placental laminin substrates (Genbacev et al., 2005).
hESCs can also be grown in serum free and feeder free conditions
by using fibronectin, TGF beta 1, bFGF, and leukemia inhibitory
factor (Amit et al., 2003). Bouhasara’s group demonstrated hESCs
culture on hTERT cell line and their subsequent differentiation
into erythrocytic cells in suspension culture method (Qiu et al.,
2005; Olivier et al., 2006).
However, there have been ambiguities about the role of
EPO/feeder layer played in erythrocytic enucleation; their pres-
ence in the final step ofmost protocols seems to remain inevitable.
This is evident from the results obtained by growing these cells
in the absence of both the above mentioned factors that result
to meager 10% enucleating efficiency (Qiu et al., 2008; Dias
et al., 2011). Whereas, inclusion of both EPO/feeder cells has
been shown to yield remarkable up to 65% enucleation effi-
ciency of these methods (Lu et al., 2008; Lapillonne et al., 2010).
Similarly, IPSCS derived erythrocytes have been shown to depend
on a feeder layer for their enucleation in final steps of matu-
ration (Lapillonne et al., 2010; Chang et al., 2011; Dias et al.,
2011; Kobari et al., 2012). Recently, heparin and insulin have been
reported to enhance enucleation efficiency of IPSCs derived ery-
throcytes in a feeder free system, but that also remains only 26%
(Kobari et al., 2012)
Another important factor is the expression of fetal Hb as a
predominant form of protein by the erythrocytes generated in
almost all these protocols (Lu et al., 2008; Lapillonne et al., 2010;
Chang et al., 2011; Dias et al., 2011; Kobari et al., 2012). This
is quite obvious because of the embryonic state of development
of both ESCs/IPSc and a more primary route of hematopoietic
development (indefinitive) likely to yield predominant expres-
sion of fetal/embryonic Hb through these protocols. However,
researchers have demonstrated the possibilities of selective
expression of adult Hb in erythrocytes by either increasing the
time length for coculture (Qiu et al., 2008), or enforced transgene
expression of RUNX1a to enhance hematopoiesis from human
ESCs and iPSCs (Tirelli et al., 2011a) reporting a higher level of β-
globin expression in differentiated erythrocytes (Ran et al., 2013).
So far, there has been no significant difference in the erythroid
expansion potential of ESCs and IPSC lines (Dias et al., 2011).
The findings reported by Douay’s group about 7–8 fold higher
erythrocytic expansion potential of human H1 ESC line in com-
parison to the human IPSCs line (IMR90-16) may be attributed
to the viral vectors used for deriving IPSC that has been reported
to decrease hematopoietic and erythrocytic expansion potential
(Feng et al., 2010). Further, epigenetic variation (integration of
viral genomes at different loci) associated with IPSCs generat-
ing methods could also contribute to these variations. Similarly,
altered hematopoietic potential have been reported for various
hESCs lines (Chang et al., 2008).
IPSCs may be advantageous in the conditions where no other
alternate in present of generating rare blood group such as
O−Rh− type of blood group. It has been postulated that only
three selected human IPSC lines may be sufficient to generate
required blood groups for almost 95.5% of patients in France
(Peyrard et al., 2011).While, no such ESC line lines with universal
blood donor group has been identified so far in the current list of
NIH-approved-for-research (Lu et al., 2008). In addition, IPSCs
can be helpful to support autologous transfusion which is highly
recommended for alloimmune patients. On the other hand, it
has promising reports to generate functional RBCs to cure rare
hemoglobinopathies such as sickle cell anemia and β-Thalassemia
(Hanna et al., 2007; Zou et al., 2011).
ERYTHROID PRECURSOR FROM STRESS ERYTHROPOIESIS
In addition to the above mentioned stem cells, researchers have
shown a significant RBCs generation potential in the extensively
proliferating erythroid precursors which are developed due to
stress conditions such as erythrolysis or hypoxia (Figure 3). The
process, generally termed as “stress erythropoiesis,” relies upon
glucocorticoids and their counter receptor interactions. There
are reports showing up to 1010-fold expansion of CB-derived
erythroid precursors using Dexamethasone as a glucocorticoid
agonist along with other growth factors, e.g., SCF, EPO, and
IGF-1 (Bauer et al., 1999; Von Lindern et al., 1999; Leberbauer
et al., 2005). Similar results could be obtained for the PB derived
erythroid precursors with the use of IL-3 along with above
mentioned cytokines (Migliaccio et al., 2002). However, these
approaches were reported to be of limited use due to their min-
imal fold expansion (<20 fold) which remain insufficient as per
clinical transfusion is concerned (Migliaccio et al., 2010).
In contrast, there have been advancements in generating
immortalized or extensively expanding erythroblast cell lines
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from embryonic stem cells with the ability to produce enucle-
ated erythrocytes in mouse (Carotta et al., 2004; Hiroyama et al.,
2008). Similar extensive expansion potential has been demon-
strated by mouse embryos (England et al., 2011), which indicated
a higher proliferation potential of embryonic erythroid progeni-
tors than postnatal cells. It is hypothesized that if postnatal ery-
throid cells could be reprogrammed by using existing techniques
to the state of embryonic erythroid progenitor cells they could
also proliferate up to a similar extent. In fact, it has been demon-
strated by Cheng’s group (Huang et al., 2013), who has demon-
strated immortalization of human CB-derived erythroblast by
using similar reprogramming factors defined by Yamasaki’s group
(Takahashi and Yamanaka, 2006). The Author has demonstrated
a significant 1068-fold expansion of CB-derived erythroblasts
(in∼12 months) in a serum-free culture. The ectopic expression
of three genetic factors Sox2, c-Myc, and a shRNA against TP53
gene enabled these cells to undergo an expanded expansion in
similar culture condition. These cells showed normal erythrob-
last phenotypes and morphology, a normal diploid karyotype
and dependence on a specific combination of growth factors for
proliferation throughout the expansion period. The coculture of
these cells with irradiated mouse OP9 cell line in the presence of
serum yield to 30% enucleation efficiency with increased fetal Hb
expression level. Similarly, Kurita et al, demonstrated immortal-
ization of human IPSC or CB derived cells by inducible expression
of TAL-1 andHPV-16-E6/E7 viral gene (Kurita et al., 2013). Thus,
it is expected that with more advancements in the reprogram-
ming technology such as the use of nonviral episomal plasmids,
synthetic RNA, and small molecules, development of more donor
cell line would facilitate generation of all blood types (Chou et al.,
2011; Hou et al., 2013; Yoshioka et al., 2013).
EX-VIVO CULTURING OF OTHER BLOOD COMPONENTS
PLATELETS
Platelets are small anuleated, discoid shaped, 1–2μm cell frag-
ments that play essential role in the maintenance of homeostasis,
stopping bleeding, or wound healing (thrombosis), inflamma-
tion, and innate immunity. There is a burgeoning use of plasma
transfusions to control massive bleeding in clinics. The combina-
tion of red blood cells, platelet concentrates, and plasma is used
for the same Platelets are present in much higher densities in ver-
tebrate blood (5.5 platelets × 1010/unit) that are generated from
megakaryocytes and their precursor cells in BM (Machlus and
Italiano, 2013).
Platelets are generated from megakaryocytic cells in the BM
niche under the regulation of various growth factors. Unlike
RBCs, committed HPCs can be easily recruited into megakary-
ocytic lineage differentiation pathways by their induction through
a single growth factor TPO. This straight forward mechanism
has tempted many researchers to mimic similar differentiation
under research settings. Like RBCs, there have been efforts to
generate platelets from all different sources, including CD34+
HSPC., ESCs/iPSCs and immature megakaryotic precursor cells.
Christian et al. have demonstrated the generation of platelet
precursor cells from human CD34+ cells by using SCF, TPO,
IL-3/IL-11, and Fetal Liver Tyrosine kinase-3 ligand (Flt-3L) in
the liquid culture system (Christian et al., 2010). However, these
precursors were shown to undergo recirculation in hematopoietic
tissues on transfusion in mice. Proulx et al. demonstrated ∼300
fold expansion of MK/CD34+ by growing UCB derived CD34+
cells with SCF, Flt-3L, TPO, and IL-6 at high concentrations
(Proulx et al., 2003, 2004). Growth of MK/CD34+ may further be
improved by optimizing culture conditions such as temp (39◦C),
O2 tension and addition of additional factors such as SDF-1α and
Nicotinamide (Guerriero et al., 2001; Mostafa et al., 2001; Cortin
et al., 2005; Giamniona et al., 2006). Matsunaga et al. (2006),
demonstrated generation of 3.4 unit platelets from UCB-CD34+
cells by using hTERT mesenchymal cell coculture method in 33
days (Matsunaga et al., 2006). Sullenberger, also reported a 3D
cartridge based perfusion bioreactor with the capacity of contin-
uously producing platelets over a period of 30 days (Sullenharger
et al., 2009). Moreover, the efforts described so far for produc-
ing platelets from UCB derived cells remain largely insufficient to
fulfill even a fraction of global demand.
Recent advancements have demonstrated enormous in vitro
platelets generation potential in pluripotent stem cells (including
iPSCs/ESCs), and a comparatively new type of cells called induced
MKs (iMKs) (Masuda et al., 2013). Matsubara et al. showed a
direct conversion of fibroblasts (mouse/human) into megakary-
ocytes (MKs) by using three factors p45NF-E2, Maf G, and Maf
K, which subsequently can release platelets (Ono et al., 2012). The
authors identified significance of these factors in generating abun-
dantMKs and platelets from human subcutaneous adipose tissues
(Matsubara et al., 2009, 2010; Ono et al., 2012).
In another approach, ESCs/IPSC mediated generation of
platelets in humans has been reported (Takayama et al., 2008,
2010). Eto et al. showed that c-Myc expression (essential for
reprogramming of IPSCs) must be reactivated transiently and
then shut-off (Takayama et al., 2010) and to ensure efficient
platelet production from human IPSCs. This transient expression
might be essential because continuous excessive c-Myc expression
in IPSCs derived MKs was shown to increase p14 (ARF) and p16
(INK4A) expression, and decreased GATA1 and NF-E2 expres-
sion, which eventually resulted MK senescence and apoptosis, as
well as impaired production of functional platelets (Takayama
et al., 2010).
More recently, Eto and colleagues have established an immor-
talizedMK cell line (MKCL) derived from human IPSCs (Masuda
et al., 2013). The immortalized MKCL could potentially provide a
stable supply of high quality platelets for transfusion medicine.
However, this method remains elusive and a detailed protocol
suitable for commercial production is yet to come.
Thus, recent findings indicate strong possibilities of a regu-
lar non donor derived platelet supply in near future. However,
there are several factors that shall be discussed to compare existing
approaches. While comparing with IPSCs/ESCs based methods,
the iMK cells (derived in these studies) are rapidly converted (2
weeks) intoMKs cells, but yield remain poor as fewer platelets (5–
10 platelets per iMK cell was generated. In contrast, single MKs
may give rise to up to 2000 platelets under in vivo conditions.
Hence, one of the important factors shall remain to be discussed
is the total number of cells that can be obtained from each cul-
tural setting. For example, Matsubara et al reported generation of
8–10 ×105 iMKs from 20 × 106 Human Derived Fibroblasts
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(HDFs) (Ono et al., 2012). HDFs are easily expanded following to
their initiation of direct conversion with limited number of trans-
fected cells, whereas, 200–300 IPS clones from 105 HDFs were
reported by Eto and colleagues in their studies. Further, 1 × 105
cultured IPSCs gave rise to 17 × 105 MKs (Takayama et al., 2010).
Thus, these results indicated low platelet production efficiency
per MK in both strategies.
Another important issue is the time taken for the produc-
tion of MKs and platelets through these protocols. iMKs and
iPSC-mediated MKs are induced in approximately 2 weeks and
2 months, respectively. However, it is yet to be established, but
MKCLs may be a much faster approach to generate platelet
sources for platelet production due to their direct expandability
into MKs.
Further IPSC-mediated MKs are not completely free from the
possible risk of some residual undifferentiated cells However, a
possible approach may be to avoid transfusion of MKs while
preferring fully matured platelets derived from these methods.
Platelets (anucleated cells) may be irradiated before transfusion
and thus may become free of any contamination of residual
undifferentiated cells.
IPSCs and MKCLs are immortal cell lines and thus are com-
paratively easy to freeze down. Similarly, HDFs are also suitable
for cryopreservationm from where they can be taken out and
used as starting materials for iMK induction. HDFs in com-
parison to platelets show better suitability for cryopreservation.
The functionality of iMKs has been assessed through their infu-
sion into irradiated immunodeficient NOD/Shi-scid/IL-2Rγnull
(NOG) mice showing normal release of human platelets in vivo
(5–10 platelets per infused IMK) cells and equal capabilities of
forming a thrombus in ex vivo conditions formation under flow
condition (Ono et al., 2012).
The iMKs are reported very recently and the early outcomes
indicate them as a valuable option for transfusion medicine.
However, there are some important issue which shall be consid-
ered in much detail such as the molecular mechanism by which
iMKs are induced through the p45NF-E2 transcriptional com-
plex, and identification of most suitable cells for direct conversion
into iMKs (or for establishment of MKCLs).
One of the important issues to be discussed here is to
explore the necessity of generating autologous iMKs through
direct conversion for clinical transfusion. Under most clinical set-
tings, platelet transfusion is done without any prior matching of
human leukocyte antigen (HLA) between the donor and recip-
ient. However, in rare conditions repeated platelet transfusions
can elicit undesired production of anti-HLA antibodies against
transfused platelets leading to an inevitable demand to identify
HLA-matched platelet donor (Stroncek and Rebulla, 2007). A
possible alternate may be provided by using autologous iMKs
based strategies. In addition, establishment of iPSC banks shall
be an alternative approach to deal with this problem. These
banks shall store homozygous HLA-typed iPSCs which would be
deposited for HLA-matched tissue transplantation (Taylor et al.,
2012). It has been demonstrated that a tissue bank from 150
selected homozygous HLA-typed volunteers could match 93%
of the UK population (Taylor et al., 2012). Yamanaka et al has
also postulated that 140 unique HLA homozygous donors shall
remain sufficient for 90% of the Japanese population (Okita et al.,
2011).
NEUTROPHILS
Neutrophils play important role in cellular immunity, but unlike
RBCs and Platelets they are not routinely collected in clinics.
Neutrophils are need to be transfused in relatively large amount,
i.e., >1010 calls every day in neutropenic patients. Ex vivo expan-
sion of neutrophils has been reported by some groups show-
ing ∼400 fold expansion from single units of UCB-CD34+ cells
(5 × 106 CD34+ cells), which equivalents to a mere 20% of the
required daily dose. Although, sufficient cells may be produced
by using PB mobilized by cytokines as demonstrated by Dick
et al. (2008), who showed ∼534 × fold (equivalent to 10 neu-
trophil units) expansion on ex vivo culture of these cells. But
this would mean one donor per recipient and supply constraints
largely remain unsolved. Similar efforts to generate neutrophils
from hESCs have also resulted in very low yields (Saeki et al.,
2008). These reports indicated the need for developing more
efficient and simple procedures to be developed first for the gen-
eration of neutrophils from either UCB-CD34+, BM derived cells
and/or houses before their commercial manufacturing could be
planned.
FACTORS REGULATING THE FATE OF COMMERCIAL BLOOD
MANUFACTURE AND FUTURE PROSPECTS
SOURCE MATERIAL SUITABILITY AND AVAILABILITY
Scientists have been trying to develop a consensus on the differ-
ent variables controlling the fate of ex vivo RBCs expansion and
clinical use. The most important of them is the source materi-
als for various methods being explored to expand RBCs in large
scale. Ideally, a source material should be a discarded material
so that no extra cost would be aided in the commercial pro-
duction process. At the same time, if a regular supply chain of
ex vivo manufactured blood has to be maintained the source
material would also be required on a regular basis i.e., unlim-
ited availability of the source material should be ensured. The
most important factor is the capability of the source cells to get
developed into the finally matured RBCs cells with absolute effi-
ciency without raising any immune response in the host i.e., it
should be non-immunogenic. The criterion fits well with umbil-
ical CB, which is available abundantly and is a waste product in
all the maternity hospitals. In fact, a significant number of trans-
fusion can be made for the patients who are suffering from rare
hemoglobinopathies (∼ 1%) by using ex vivo cultivated RBCs
units that might be obtained from these sub threshold units of CB
(>90ml) discarded regularly. Each discarded unit of CBmay gen-
erate 10–75 RBCs products which might be useful in transfusions
for rare hemoglobinopathies (Peyrard et al., 2011). Similarly,
Leukopheresis is routinely done in clinical centers where trans-
fusions are made to treat various leukemia patients. In these
protocols the leuko-reduction buffy coat is produced as a byprod-
uct and this contains significant amounts of RBCs producing cells
(equivalent to umbilical CB) (Zhou et al., 2009).The proof-of-
the concept that these ex-vivo cultivated cells may be of clinical
use was provided by demonstrating successful transfusion of
CD34+ cells which were obtained from a G-CSF mobilized donor
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(Migliaccio et al., 2010). Apart from UCB derived CD34+ cells,
ESCs, and hiPSCs as described in previous sections might serve as
a potential source for regular manufacturing processes with the
advancement in technologies.
QUANTITATIVE ISSUES
The most frequently transfused blood component, RBCs, are
present in 2 × 1012 cells/unit (200ml of blood) with an expected
cell density of 3 × 106 cells/ml. According to theWHO data>100
million units of blood is collected every year worldwide. In order
to replace this huge volume with synthetic blood/blood compo-
nents, an extremely large amount of ingredients along with skilled
manpower would be an inevitable requirement. It is hypothe-
sized that a cell density of 5 × 107 cells/ml would be essential to
produce regularly to support this much demand. Further, accord-
ing to an assumption, manufacturing of a single unit of blood
by using present static culture methods, would require 660 liters
of culturing medium and 9500 lab scale 175 cm2 culturing flasks
(70ml medium/flask) (Timmins and Nielsen, 2009; Zeuner et al.,
2012).
Ensuring such a high concentration of RBCs would attract
development of more automated methods like bioreactors that
might be helpful in reducing the culturing assets and associated
labor. Fortunately a wealth of information regarding the use of
various types of bioreactors for HSCs expansion has been accu-
mulating during the last two decades. This could help researchers
achieve required cell density. It was reported by Timmins et al that
similar density of RBCs as in static culture can be produced in a
wave bioreactor (Timmins et al., 2011). A maximum cell density
of 107 cells/ml was also reported in a stirred small scale bioreac-
tor (Ratcliffe et al., 2012). Housler et al, reported a massive yield
of 2 × 108 cells/ml in a hollow fiber bioreactor (Housler et al.,
2012). These 3D bioreactors can be scaled up with current design
to produce 1–2 units of RBCs in 3–4 weeks of time. These reports
indicate possibilities of ensuring a regular production of large
amounts of RBCs, however, a number of factors such as degree
of cell maturation and various cultural parameters are yet to be
defined in a more elaborated manner.
Further, an important achievement could be the develop-
ment of methods to commit the source material directly into the
erythropoietic lineages reducing both the time and cost of pro-
duction. There are few preliminary reports about various efforts
to define alternate sources such as (i) generation of erythropoi-
etic cell lines from ESCs/IPSCc (i) reprogramming any somatic
cells directly into erythroblasts by passing the pluripotent state
through over expression of suitable genes.
This has been reported for megakaryocytic differentiation also
where human fibroblast cells are directed to differentiate directly
into megakaryocytic cells through over expression of p45NF and
E2/MaF transcription factors (England et al., 2011; Wang et al.,
2011). Cheng’s group reported in humans the differentiated ery-
throid cells obtained from human embryo might be used as
a potential initial source for RBCs production (Huang et al.,
2013; Kurita et al., 2013). Thus, it is conceivable that with more
advancements in the culture methods and initial source mate-
rial a significant amount of RBCs could be produced for limited
clinical uses.
GROWTH FACTORS
Growth factors used in various phases of ex vivo culturing should
also be explored to regulate the fate of commercial manufactur-
ing. Both the “concentration” and “time” of their administration
would play an important role in the optimization of the expan-
sion process. It is also to be noticed that there are various growth
factors which express gene polymorphism, for example,>260 iso-
forms of human glucocorticoids receptors are expressed which
are likely to differ in their potency and effects. In order to secure
a large scale production of RBCs, it is conceivable to determine
an in depth knowledge about the functioning and efficiency of
various isoforms through high throughput screening methods
regularly. A good example might be the use of reverse phase pro-
teomic analysis of CD34+ cells to define molecular mechanism
of signaling pathways activated during erythroid differentiation.
Recently, similar studies have been reported by various groups
showing activation of different set of gene(s) in CD34+ cells and
erythroblasts. Genes that are involved in the inhibition of apop-
tosis, transcription, and proliferation are more active in CD34+
cells, whereas erythroblasts predominantly express those genes
which play important roles in regulation of cell cycle, transcrip-
tion and translation (Ratcliffe et al., 2012). This information
may be of use if specific pharmacological agents enhancing ery-
throcytic pathways and blocking apoptotic pathways may be
introduced at various phases of ex vivo expansion.
BIOPHYSICAL AND BIOCHEMICAL PARAMETERS
Generation of clinical grade RBCs would require development of
stringent quality checks for ex vivo expanded RBCs. The major
parameters would include determination of antigenic profiles,
hemoglobin contents and physical progenies derived from these
culture processes. As described by various laboratories ex vivo
generated RBCs are slightly macrocytic but normal in size. These
RBCs also expresses a great level of α-hemoglobin stabilizing pro-
teins (AHSP), BCL11A and globin gene with great donor to donor
heterogeneity (Keel et al., 2008). It is also reported that ex vivo
generated erythroblasts contain γ-globin in a slightly greater
amount in comparison to RBCS which are generated in vivo
(0.12–0.20 pg/cell with respect to total protein content of 18.723.7
per cell) (Lu et al., 2008).
ANTIGENIC PROFILE
Surface antigens are vital for the function of RBCs and a large
number of surface antigen have been identified on the surface of
mature RBCs. Ex vivo generated RBCs are reported to express nor-
mal level of antigens present on both the Ankyrin A (GPA, M/N,
Ena FS, RhAO, and band 3/4.1 R) and Glycophorin B complex,
the urea transporter, the complement receptor, and receptors that
protect RBCs from complement mediated lysis Recent reports
about the surface antigenic analysis of the ex vivo generated RBCs
ensured that appropriate level of surface antigen such as band
3 and Rh antigen is assured at the beginning of the maturation
process (Satchwell et al., 2011).
ETHNICITY
Recently, there have been some reports demonstrating effects
of ethnicity on the source material used for ex vivo expansion.
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African-American donor derived MNC were found to be found
to be more useful as per as fold expansion is concerned since
they could be expanded up to 14–40 fold in comparison to the
Caucasian population derived MNCs which give rise to 1.7–30
fold expansion (Tirelli et al., 2011b; Carilli et al., 2012)
ENUCLEATION OF RBCs
Since, Ex vivo expanded RBCs shall essentially be evaluated for
their degree of terminal maturation in all the production units.
Hence, high level of enucleation of maturing erythroblast is
an inevitable requirement. Erythroblasts derived from ESCs are
demonstrated to yield >60% enucleated RBCs (Lu et al., 2008)
while the nucleation efficiency of maturing erythroblast from
ups could be demonstrated to a mere 4–10% of RBCs produced
(Lapillonne et al., 2010). Recently, there have been efforts to
define the factors regulating enucleation efficiency of RBCs indi-
cating the significance of proteins such as Huston deacetylase
(specifically HDAC-2 isoform) which are required for chromatin
condensation and enucleation in mice fetal erythroblast (Chang
et al., 2011). Since, glucocorticoids play important negative reg-
ulators for these proteins as mentioned above, application of
molecular agents which specifically activates HDACs could be
employed in phase-3 cultures to enhance the enucleation yields.
As mentioned in a number of reports, co -culturing of matu-
rating erythroblast along with stromal cells may enhance their
terminal maturation, but on the other hand it might impose an
additional risk of poorly defined potentially immunogenic and/or
infectious agent which may compromise the production of GMP
for RBCs in the developmental process. These issues indicate the
need for the development of biochemical alternatives to avoid the
use of stromal co-cultures in these protocols. There are prelimi-
nary reports on the use of drugs likeMifepristone and plasmanate
which are defined to have similar effects on promoting enucle-
ation efficiency during ex vivo expansion of RBCs (Miharada
et al., 2006). In addition, factors promoting the functioning of
proteins involved in vesicle trafficking such as “vaccuoline” may
also be used to improve the enucleation efficiency if phase-3
cultures (Keerthivasan et al., 2010).
PRODUCTION COST
The regular commercial production of RBCs would be heavily
affected by their cost of production. According to a hypothetical
estimation, producing RBCs in desired range would cost approx-
imately $8000–15000 per unit (Timmins and Nielsen, 2009;
Zeuner et al., 2012). Whereas, the hospital cost for leuco-reduced
RBCs is only $225 that is significantly lower in comparison to
synthetic product. There are situations such as matching of rare
phenotypes of RBCs and the present cost of a phenotypically
matched unit of RBCs is ∼$700–1200. Producing blood on a
commercial scale would require a huge monetary investment and
it will be difficult to keep the momentum in the direction of
R&D for developing more and more efficient protocols due to
lack of money especially in low income grade countries. It would
be important to find out immediate goals which can be achieved
from the outcomes of the existing research findings to gener-
ate alternate sources of money. For example, immediate use of
these small scale products may be useful in developing various
immediately achievable goals. There are few promising examples,
such as the use of ex vivo cultured cells for Reagent RBCs diagnos-
tics in specifically alloimmunized patients and they can be used
as drug delivery vehicles for personalized therapies. The require-
ment of relatively small no. of RBCs in these methods makes them
most suitable for these kinds of assays, for example, ∼ 2 × 108
RBCs will be sufficient to perform 100× s of these assays in clin-
ical settings and with the present methodologies 109–1010 RBCs
can be expanded regularly.
SUMMARY
In brief, it seems feasible that commercial production of RBCs
may take place in near future. There are enough technological
evidences available supporting the concept and with the advent of
newer source materials, optimal methods for ex vivo cultivation of
RBCs and highly stringent, comprehensive quality control, ana-
lytical measures, the regular production of blood may take place
to support a smaller fraction of the population at least. All the
three major sources of like CD34+− HSCs (UCB, PB, and BM
derived cells), hESCs and, iPSCs have enough potential of gener-
ating huge amounts of RBCs and if more sophisticated methods
are generated such as development of erythropoietic hESC cell
lines, it would be possible to generate an unlimited source of
initial source material for the production measures.
Moreover, with the development of more in depth knowledge
about the molecular mechanisms involved in various stages of
ex vivo erythropoiesis. It would become more efficient to support
even larger population’s blood demands. The fundamental infor-
mation shall also be helpful in developing pharmacological alter-
nates for the various stages of erythropoietic development which
presently depend upon their interactions with feeder cell support
systems in most of the protocols. Development of pharmacologi-
cal alternates is essential to simplify the production processes for
clinical grade blood. Avoiding the need of feeder cells may also
help in reducing the unexpected risks associated with their use
due to undefined immunogenic and infectious exposures which
are likely imposed to the recipients by animal derived feeder cell
support methods. The omission of feeder cells from ex vivo RBCs
expansion protocols would also simplify the commercial scale
production methods and may also be helpful in reducing the cost
of production. As per as cost is concerned, a small fraction of the
population may be capable of bearing the cost of commercially
produced blood in economically developed countries. However,
more liberal government policies such as lowering both the sale
and services taxes, provisions for subsidized input materials (like
electricity, water, etc.), direct subsidy offered for the products
may be helpful in supporting the low cost production of blood.
Besides that, a small amount of remuneration may also be gener-
ated from the various smaller/specific products such as reagent
RBCs, RBCs for the specific drug delivery targets to cure rare
hemoglobinopathies and thatmight support the ongoing research
and development in the same direction.
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